Natural GLP-1 Revolution: GlucoVantage Dihydroberberine Shows Unprecedented Results in Blood Sugar and Body Composition Research

The supplement industry has witnessed a seismic shift in recent months, as mainstream attention turns toward GLP-1 receptor agonists like semaglutide for their remarkable effects on blood sugar control and body composition. While these pharmaceutical options have garnered significant attention, a natural alternative has also been demonstrating incredible effects in research: dihydroberberine. Sold as GlucoVantage® by NNB Nutrition, dihydroberberine is a patented,[1] highly-bioavailable form of berberine shown to outperform berberine itself.

NNB Nutrition’s GlucoVantage: A Natural Alternative to GLP-1?!

Natural GLP-1 Revolution: GlucoVantage Dihydroberberine Shows Unprecedented Results in Blood Sugar and Body Composition Research

GlucoVantage® dihydroberberine redefines metabolic health by boosting GLP-1 levels by 95% in new research. Its superior bioavailability and multi-faceted benefits—like better body composition, lipid profiles, and oxidative stress reduction—position it as a groundbreaking natural alternative to GLP-1 drugs.

This revelation comes at a critical time, as new research demonstrates that dihydroberberine not only matches but potentially exceeds expectations in key metabolic markers, particularly in its ability to increase GLP-1 levels naturally. In a groundbreaking internal study, researchers found that dihydroberberine increased GLP-1 levels by 95% compared to control groups in metabolically challenged subjects.[2] These results have sparked intense interest in the scientific community, especially given dihydroberberine’s established safety profile and superior bioavailability compared to standard berberine.[3,4]

  • A safer, multi-faceted approach to GLP-1

    But what makes these findings particularly compelling isn’t just the impressive numbers – it’s the broader implications for metabolic health. While pharmaceutical GLP-1 agonists work through direct receptor stimulation, dihydroberberine appears to work through multiple complementary pathways, supporting not only GLP-1 production but also enhancing insulin sensitivity and reducing oxidative stress.[4] This multi-faceted approach may explain why research subjects showed significant improvements in body composition while maintaining lean mass – a crucial advantage over some pharmaceutical options.

    In this deep dive, we’ll examine the latest research behind GlucoVantage dihydroberberine, exploring how this natural compound achieves its remarkable effects, and why it’s positioning itself as a leading option for those seeking to optimize their metabolic health through natural means.

    Before we dive in, sign up for our NNB Nutrition news alerts so you don’t miss out on any of the novel ingredient developer’s latest achievements:

Subscribe to PricePlow's Newsletter and Alerts on These Topics

Topic Blog Posts YouTube Videos Instagram Posts
Dihydroberberine
GlucoVantage
NNB Nutrition

Background on GLP-1 Signaling

Our bodies have an incredibly sophisticated system for regulating metabolism and appetite, and at the center of this system is a hormone called glucagon-like peptide-1 (GLP-1). This peptide hormone, secreted by specialized cells in our intestines after meals, acts as a crucial metabolic messenger throughout the body.[5]

When GLP-1 is released, it triggers a cascade of beneficial metabolic effects: It helps reduce appetite, slows down how quickly food moves through the stomach, and – perhaps most importantly – tells the pancreas to release insulin when blood sugar levels are elevated.[6] This coordinated response helps ensure that nutrients are properly processed and blood sugar levels stay well-controlled.

  • The creation of pharmaceutical GLP-1 agonists

    The pharmaceutical industry recognized the immense therapeutic potential of this pathway over a decade ago. By developing drugs that mimic GLP-1’s effects (called GLP-1 receptor agonists), companies like Novo Nordisk have created powerful treatments for both diabetes and obesity. These medications essentially “hijack” our body’s natural GLP-1 system, leading to impressive weight loss results and improved metabolic health biomarkers.[7]

  • Numerous pharma side effects, but natural alternatives exist

    However, pharmaceutical GLP-1 agonists are rife with severe side effects, ranging from gastrointestinal distress to muscle loss to excessively long stomach emptying (gastroparesis) to risk of cancer and even blindness.[8-13]

    The good news is that they aren’t the only way to engage this powerful metabolic pathway. Research has shown that certain natural compounds can also influence GLP-1 signaling – albeit through slightly different mechanisms.[2,14-21] Rather than directly mimicking GLP-1, these compounds work by enhancing the body’s own GLP-1 production and improving how cells respond to GLP-1’s signals.

    This brings us to one of the most promising natural GLP-1 modulators: dihydroberberine. This enhanced form of berberine has demonstrated remarkable abilities to boost GLP-1 levels and improve metabolic function in multiple studies – suggesting it may offer a natural alternative for those seeking to optimize their GLP-1 pathway.[2]

    Let’s explore exactly how this compound works and what the research shows about its effects.

The Bioavailability Advantage of Dihydroberberine

One of the most compelling advantages of GlucoVantage dihydroberberine (DHB) over standard berberine is its dramatically improved bioavailability. A groundbreaking crossover trial by Moon et al. demonstrated that dihydroberberine achieves significantly higher plasma concentrations compared to an equivalent dose of berberine.[4] This enhanced absorption translates into better results with lower doses, making GlucoVantage a more efficient option for those seeking berberine’s metabolic benefits.

NNB Nutrition's GlucoVantage Dihydroberberine GLP-1 Internal Data

  • Superior Absorption Mechanisms

    The enhanced bioavailability of dihydroberberine isn’t just a coincidence – it’s rooted in the compound’s unique molecular structure and how it interacts with our digestive system. Research has revealed a significant hurdle: standard berberine must first be converted into dihydroberberine by gut bacteria before it can be effectively absorbed.[3]

    This conversion process creates a bottleneck in berberine’s absorption, as it depends entirely on the activity and health of intestinal bacteria. Dihydroberberine, however, bypasses this limitation entirely since it’s already in its absorbable form. Once absorbed, DHB is then converted back into berberine in the intestinal tissue – precisely where it needs to be for optimal effectiveness.[3]

  • Clinical Evidence of Enhanced Bioavailability

    The superiority of dihydroberberine’s absorption was clearly demonstrated in Moon’s clinical study, which found that DHB achieved:[4]

    • An area under the curve (AUC) approximately 5 times higher than standard berberine
    • A peak concentration (Cmax) that was more than 3 times greater
    • These impressive results were achieved with just 100-200mg of dihydroberberine compared to 500mg of standard berberine
  • Lower Effective Dosing

    This enhanced bioavailability means that much lower doses of GlucoVantage can achieve the same or better results than standard berberine. While typical berberine protocols often call for doses of 1500mg per day split into multiple servings, GlucoVantage can achieve comparable or superior effects at just 200-600mg daily.[4]

    This lower dosing requirement offers several advantages:

    1. Reduced pill burden – fewer capsules needed per day
    2. Better compliance – easier to stick to the protocol
    3. Berberine vs. GlucoVantage Dihydroberberine

      There was a lot of individual variance in dihydroberberine effectiveness in the high-dose DHB test, but it’s clear that DHB supplementation is vastly more effective at increasing serum berberine levels. D100 = 100 mg DHB, D200 = 200 mg DHB, B500 = 500 mg berberine. ng/mL = nanograms per milliliter of blood.[4]

    4. Improved comfort – less chance of gastrointestinal issues that can occur with high-dose berberine
    5. More cost-effective – GlucoVantage may cost more per gram, but its superior absorption means less is needed

    For those who have found standard berberine’s high dosing requirements challenging to maintain, GlucoVantage represents a more practical and efficient alternative that doesn’t compromise on results.

    The above benefits are discussed in more detail in two articles linked below. You can bookmark them for later, but let’s continue to the new preclinical data:

Head-to-Head: Dihydroberberine vs Berberine and Eriomin

With the data mentioned above and the new preclinical research, there’s a strong argument to be made for GlucoVantage dihydroberberine:

  • Dihydroberberine vs Standard Berberine: A Clear Victory for Bioavailability

    As discussed above, dihydroberberine’s most striking advantage over standard berberine lies in its dramatically improved bioavailability profile, with researchers finding that it achieves plasma concentrations roughly 5 times higher than the same dose of berberine.[3,4]

    This leads to far smaller doses required for similar or better glycemic results, needing fewer capsules and reduced risk of gastrointestinal issues.

    That’s all been known — so what’s in the new research?

  • Dihydroberberine: Nature’s Answer to GLP-1 Modulation

    In a groundbreaking comparison, GlucoVantage has shown remarkable results when compared to semaglutide in preclinical models using a high-fat diet. Most notably, GlucoVantage dihydroberberine increased GLP-1 levels by 95% compared to the high-fat diet control group![2]

    Berberine vs. Dihydroberberine

    A study published in early 2022 showed that NNB Nutrition’s GlucoVantage dihydroberberine outperformed higher doses of normal berberine in elevating plasma berberine and reducing blood sugar and insulin levels!

    The weight loss effects were similarly impressive. While semaglutide is known for significant weight reduction, dihydroberberine demonstrated phenomenal efficacy in the high-fat diet model, with GlucoVantage reducing body fat mass by 27.5%.[2] This is particularly noteworthy given dihydroberberine’s natural origin and established safety profile.

    In terms of lipid profile improvements, GlucoVantage delivered significant results:[2]

    • LDL cholesterol reduction: 59.8%
    • Triglyceride reduction: 25.5%
    • Total cholesterol reduction: 40.5%

    While semaglutide showed slightly better numbers in some categories (66.9% LDL reduction), dihydroberberine’s natural mechanism of action and lack of severe side effects make it an extremely compelling alternative.

  • Dihydroberberine vs Eriomin: Superior GLP-1 Activation

    When comparing dihydroberberine to other natural GLP-1 modulators like Eriomin, the contrast becomes even more striking. While Eriomin (standardized to 70% eriocitrin) has shown the ability to increase GLP-1 by 17% in participants with high fasting blood sugar,[18] NNB’s new data shows that GlucoVantage demonstrated a 95% increase in GLP-1 versus the placebo high-calorie diet group, showcasing significantly greater potency.[2]

    In glycemic control measures, NNB’s data shows that dihydroberberine again outperformed Eriomin. While Eriomin supplementation resulted in a 5% reduction in fasting blood glucose,[18] GlucoVantage showed more pronounced effects on overall glucose regulation and insulin sensitivity, reducing serum insulin by 58.6% in the high-calorie diet group.[2]

    This comprehensive comparison demonstrates that dihydroberberine stands as a leading option for metabolic health support, offering comparable or superior results to both pharmaceutical and natural alternatives, while maintaining an excellent safety profile.

Additional Benefits of GlucoVantage

The advantages of GlucoVantage extend well beyond blood glucose management, especially with respect to its synergistic effects with exercise, impact on oxidative stress, and influence on body composition:

Berberine vs. Dihydroberberine: Blood Sugar and Insulin

Both the 100 mg and 200 mg doses of dihydroberberine were vastly more effective than 500 mg regular berberine at increasing serum berberine concentrations. D200 improved insulin signaling just as much as the 2.5x larger dose of berberine. The D200 dose also improved glucose disposal more than the 500 mg berberine![4]

  • Synergistic Effects with Exercise

    Perhaps one of the most intriguing new discoveries is how GlucoVantage may enhance the benefits of regular exercise. When combined with a consistent exercise routine, dihydroberberine supplementation has demonstrated remarkable synergistic effects:

    The combination of GlucoVantage and exercise led to a substantial 22.7% reduction in fat content compared to exercise alone, while simultaneously supporting a 15.7% increase in lean body mass.[2] This suggests that dihydroberberine may help optimize body composition changes during training programs.

    What makes this interesting is that these improvements weren’t just about the numbers on the scale – the dihydroberberine plus exercise group showed superior results in both fat loss and muscle preservation compared to exercise alone, pointing to more favorable overall body composition changes.[2]

  • Powerful Antioxidant Support

    GlucoVantage also had a significant impact on oxidative stress markers. When combined with exercise, NNB’s research shows that dihydroberberine supplementation led to powerful antioxidant effects:[2]

    • A remarkable 34.2% decrease in Reactive Oxygen Species (ROS) compared to the exercise-only group
    • Enhanced antioxidant enzyme activities, suggesting improved cellular protection against oxidative damage

    This reduction in oxidative stress is particularly noteworthy because elevated ROS levels are often associated with metabolic dysfunction and can impair athletic recovery. By helping to manage oxidative stress, GlucoVantage may support both metabolic health and exercise recovery.

  • Body Composition Benefits

    The impact of GlucoVantage on body composition has been particularly impressive in research settings:

    • A significant 27.5% reduction in body fat compared to control groups
    • Preserved lean mass during fat loss, suggesting a selective fat-reducing effect[2]
    • Enhanced fat loss results when combined with exercise (22.71% greater reduction in fat content when compared to exercise alone)[CITATION – NNB Internal Research, 2024]

    Not just weight loss – preservation of lean mass!

    GlucoVantage Dihydroberberine Bioavailability

    We’ve long said that GlucoVantage dihydroberberine has 5x the bioavailability if traditional berberine. In our ‘5X’ article, we explore the very well-designed study that demonstrated this.

    What’s noteworthy is that these changes in body composition were achieved while maintaining lean muscle mass – a crucial factor for long-term metabolic health and physical performance. This selective effect on fat tissue while preserving muscle makes GlucoVantage an excellent option for those seeking to improve their body composition, whether they’re athletes or individuals focused on general health optimization.

    There are a couple of powerful meta-analyses showing improved weight loss from standard berberine,[22,23] so this data isn’t terribly surprising, but most berberine weight loss research doesn’t discuss preservation of lean mass, which is what we’re more interested in, especially in the context of GLP-1 drugs.

  • Improved Lipid Profiles

    GlucoVantage also demonstrated impressive effects on blood lipids:[2]

    • 25.5% reduction in triglycerides
    • 40.5% reduction in total cholesterol
    • 59.8% decrease in LDL cholesterol

    These improvements in lipid profiles, combined with the other benefits we’ve discussed, suggest that GlucoVantage may offer comprehensive support for metabolic health beyond just blood sugar control.

    The multi-faceted benefits of GlucoVantage – from its synergistic effects with exercise to its powerful antioxidant properties and positive impact on body composition – make it the natural option for comprehensive metabolic health support. Whether used as part of an exercise program or for general health optimization, the research suggests that dihydroberberine’s benefits extend well beyond its primary role as a glucose disposal agent.

Practical Applications, Future Research, and Concluding Thoughts

Formulator's Corner #14: An NNB Nutrition Holiday GDA Powered by GlucoVantage Dihydroberberine

Are you and your customers ready for the holiday calories? If not, formulate something like our GlucoVantage Holiday GDA in Formulator’s Corner #14

The emergence of GlucoVantage dihydroberberine as a potent GLP-1 modulator opens exciting possibilities for those seeking to optimize their metabolic health through natural means.

It can be formulated in standalone supplements, but forward-thinking brands combine it with other glucose disposal agents and metabolism-supporting ingredients to create comprehensive metabolic health formulas. An example stack would include NNB Nutrition’s CaloriBurn GP and MitoBurn L-BAIBA, both covered in our popular WAT to BAT article.

Research also suggests taking it with meals provides optimal benefits for glucose disposal.[4] This makes logical sense given its mechanisms of action through multiple pathways, including enhanced GLP-1 secretion.

  • Areas for Future Research

    While the current data is compelling, several research directions could further enhance our understanding:

    1. Long-term human trials examining dihydroberberine’s effects on body composition when combined with resistance training
    2. Studies comparing various dosing protocols (with meals vs. fasted)
    3. Research on potential synergistic effects when combined with other natural GLP-1 modulators
    4. Investigation into dihydroberberine’s impact on muscle protein synthesis and preservation during caloric restriction
  • Advanced Glycation Endproducts w/ NNB's GlucoVantage

    GlucoVantage from NNB Nutrition, featuring dihydroberberine, isn’t just for managing healthy blood sugar. It supports better body composition, boosts energy, and may lower the risk of chronic illnesses. But today, we focus on its ability to combat Advanced Glycation Endproducts.

  • Target Populations

    The research suggests dihydroberberine may be particularly beneficial for:

    • Individuals seeking to optimize their response to carbohydrates, especially around training
    • Dieters looking to support healthy body composition while maintaining muscle mass
    • Those interested in natural alternatives to pharmaceutical GLP-1 modulators
    • Athletes and fitness enthusiasts focusing on body recomposition
    • Anyone seeking to maintain metabolic health while following a higher-carbohydrate diet

    Importantly, dihydroberberine appears to shine brightest when combined with exercise – showing enhanced fat reduction and lean mass preservation compared to exercise alone.[2] This makes it an especially attractive option for the physically active population.

  • The Path Forward

    As our understanding of GLP-1 signaling continues to evolve, GlucoVantage dihydroberberine stands out as a promising natural option that works through multiple complementary pathways. While pharmaceutical GLP-1 agonists have captured headlines, dihydroberberine offers a more holistic approach – supporting not just GLP-1 secretion, but also enhancing insulin sensitivity, reducing oxidative stress, and promoting healthy body composition.

    NNB Nutrition: We Create Ingredients

    The future looks bright for this innovative ingredient, but as with any supplement, results will be optimized when combined with proper diet, regular exercise, and overall healthy lifestyle choices.

    To dive deeper into the science behind dihydroberberine’s superior bioavailability and real-world performance, check out our detailed analyses:

    For those interested in staying updated on the latest developments in dihydroberberine research and applications, sign up for our NNB Nutrition news:

Subscribe to PricePlow's Newsletter and Alerts on These Topics

Topic Blog Posts YouTube Videos Instagram Posts
Dihydroberberine
GlucoVantage
NNB Nutrition

All PricePlow Articles Mentioning GlucoVantage / Dihydroberberine

About the Author: PricePlow Staff

PricePlow Staff

PricePlow is a team of supplement industry veterans that include medical students, competitive strength athletes, and scientific researchers who all became involved with dieting and supplements out of personal need.

The team's collective experiences and research target athletic performance and body composition goals, relying on low-toxicity meat-based diets.

No Comments | Posted in , , | Tagged , , , , , , , , .

References

  1. Wells, Shawn, et al; “Administration of berberine metabolites”; United States Patent and Trademark Office. United States patent US10278961B2; April 19, 2016. https://patents.google.com/patent/US10278961B2/en
  2. NNB Internal Research, 2024. (Available with NDA)
  3. Feng, Ru, et al. “Transforming Berberine into Its Intestine-Absorbable Form by the Gut Microbiota.” Scientific Reports, vol. 5, no. 1, 15 July 2015, p. 12155, doi:10.1038/srep12155. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502414/
  4. Moon, Jessica M et al. “Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial.” Nutrients vol. 14,1 124. 28 Dec. 2021, doi:10.3390/nu14010124 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746601/
  5. Shah, Meera, and Adrian Vella. “Effects of GLP-1 on Appetite and Weight.” Reviews in Endocrine & Metabolic Disorders, vol. 15, no. 3, 1 Sept. 2014, pp. 181–187, doi:10.1007/s11154-014-9289-5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4119845/
  6. Drucker, Daniel J, and Michael A Nauck. “The Incretin System: Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes.” The Lancet, vol. 368, no. 9548, Nov. 2006, pp. 1696–1705, doi:10.1016/s0140-6736(06)69705-5. https://pubmed.ncbi.nlm.nih.gov/17098089/
  7. Mihaela Simona Popoviciu, et al. “Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.” International Journal of Molecular Sciences, vol. 24, no. 13, 21 June 2023, pp. 10449–10449, doi:10.3390/ijms241310449. https://pmc.ncbi.nlm.nih.gov/articles/PMC10341852/
  8. Gorgojo-Martínez, Juan J., et al. “Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.” Journal of Clinical Medicine, vol. 12, no. 1, 1 Jan. 2023, p. 145, doi:10.3390/jcm12010145. https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/
  9. Bikou, Alexia, et al. “A Systematic Review of the Effect of Semaglutide on Lean Mass: Insights from Clinical Trials.” Expert Opinion on Pharmacotherapy, 17 Apr. 2024, doi:10.1080/14656566.2024.2343092. https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2343092
  10. Kalas, M Ammar, et al. “Medication-Induced Gastroparesis: A Case Report.” Journal of Investigative Medicine High Impact Case Reports, vol. 9, Jan. 2021, p. 232470962110519, doi:10.1177/23247096211051919. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529310/
  11. Chaudhry, Ahtshamullah, et al. “Tendency of Semaglutide to Induce Gastroparesis: A Case Report.” Cureus, vol. 16, no. 1, 1 Jan. 2024, p. e52564, doi:10.7759/cureus.52564. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874596/
  12. Yang, Zuozhang, et al. “GLP-1 Receptor Agonist-Associated Tumor Adverse Events: A Real-World Study from 2004 to 2021 Based on FAERS.” Frontiers in Pharmacology, vol. 13, 25 Oct. 2022, doi:10.3389/fphar.2022.925377. https://pmc.ncbi.nlm.nih.gov/articles/PMC9640975/
  13. Hathaway, Jimena Tatiana, et al. “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.” JAMA Ophthalmology, 3 July 2024, doi:10.1001/jamaophthalmol.2024.2296. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255
  14. Yu, Yunli, et al. “Berberine Induces GLP-1 Secretion through Activation of Bitter Taste Receptor Pathways.” Biochemical Pharmacology, vol. 97, no. 2, Sept. 2015, pp. 173–177, doi:10.1016/j.bcp.2015.07.012. https://pubmed.ncbi.nlm.nih.gov/26206195/
  15. Sun, Yongning, et al. “Restoration of GLP-1 Secretion by Berberine Is Associated with Protection of Colon Enterocytes from Mitochondrial Overheating in Diet-Induced Obese Mice.” Nutrition & Diabetes, vol. 8, no. 1, 24 Sept. 2018, doi:10.1038/s41387-018-0061-x. https://pmc.ncbi.nlm.nih.gov/articles/PMC6155143/
  16. Ribeiro, Carolina B., et al. “Effectiveness of Eriomin® in Managing Hyperglycemia and Reversal of Prediabetes Condition: A Double‐Blind, Randomized, Controlled Study.” Phytotherapy Research, vol. 33, no. 7, 11 June 2019, pp. 1921–1933, doi:10.1002/ptr.6386. https://pmc.ncbi.nlm.nih.gov/articles/PMC6618084/
  17. Yaribeygi, Habib, et al. “Boosting GLP-1 by Natural Products.” Advances in Experimental Medicine and Biology, vol. 1328, 2021, pp. 513–522, doi:10.1007/978-3-030-73234-9_36. https://pubmed.ncbi.nlm.nih.gov/34981502/
  18. Thais Borges Cesar, et al. “Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial.” Journal of Medicinal Food, vol. 25, no. 11, 1 Nov. 2022, pp. 1050–1058, doi:10.1089/jmf.2021.0181. https://pmc.ncbi.nlm.nih.gov/articles/PMC9700344/
  19. Wu, Wei, et al. “Berberine Enhances the Function of Db/Db Mice Islet β Cell through GLP-1/GLP-1R/PKA Signaling Pathway in Intestinal L Cell and Islet α Cell.” Frontiers in Pharmacology, vol. 14, 4 July 2023, doi:10.3389/fphar.2023.1228722. https://pmc.ncbi.nlm.nih.gov/articles/PMC10352779/
  20. Mostafa Araj-Khodaei, et al. “Berberine-Induced Glucagon-like Peptide-1 and Its Mechanism for Controlling Type 2 Diabetes Mellitus: A Comprehensive Pathway Review.” Archives of Physiology and Biochemistry, 3 Nov. 2023, pp. 1–8, doi:10.1080/13813455.2023.2258559. https://pubmed.ncbi.nlm.nih.gov/37921026/
  21. Yang, Wei-Li, et al. “Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction.” ˜the œAmerican Journal of Chinese Medicine, 8 Feb. 2024, pp. 1–22, doi:10.1142/s0192415x24500113. https://pubmed.ncbi.nlm.nih.gov/38351702/
  22. Asbaghi, Omid, et al. “The Effect of Berberine Supplementation on Obesity Parameters, Inflammation and Liver Function Enzymes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Clinical Nutrition ESPEN, vol. 38, Aug. 2020, pp. 43–49, doi:10.1016/j.clnesp.2020.04.010; https://pubmed.ncbi.nlm.nih.gov/32690176/
  23. Ilyas, Zahra, et al. “The Effect of Berberine on Weight Loss in Order to Prevent Obesity: A Systematic Review.” Biomedicine & Pharmacotherapy, vol. 127, July 2020, p. 110137, doi:10.1016/j.biopha.2020.110137; https://www.sciencedirect.com/science/article/pii/S0753332220303292

Comments and Discussion (Powered by the PricePlow Forum)